⏳ Fetching live dividend data...
Home › Calculator › AMAM Dividend Calculator 2026
Ambrx Biopharma Inc. · NYSE
Price: $28.00 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in AMAM → $52.3K in 10 years · $3,125.27/month
Ambrx Biopharma Inc. operates as a clinical-stage biotechnology company focused on the discovery and development of precisely engineered biologic medicines. The firm utilizes its unique expanded genetic code technology platform to create these advanced therapies. Leading its pipeline is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is currently undergoing evaluation in several clinical investigations. These include pivotal Phase 2/3 trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer, alongside studies for other solid tumors. Additionally, Ambrx is progressing two earlier-stage drug candidates: ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for prostate cancer and other solid tumor indications; and ARX305, an anti-CD70 ADC, currently in investigational new drug (IND)-enabling studies for potential applications in renal cell carcinoma and other cancers. The company's portfolio also encompasses multiple immuno-oncology programs. Among these are ARX822, a fab-small molecule bispecific therapeutic in preclinical development for various cancers, and ARX102, an immuno-oncology IL-2 pathway agonist intended to stimulate the patient's immune system by targeting beta and gamma receptors on cytotoxic T cells. Founded in 2003 and headquartered in La Jolla, California, Ambrx Biopharma Inc. has established significant collaborations with various pharmaceutical partners, including Bristol Myers Squibb Company, AbbVie Inc., BeiGene, Sino Biopharmaceutical Co., Ltd., NovoCodex, and Elanco Animal Health.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open AMAM position with:
Real after-tax yield depends on where you live and how you hold AMAM.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 7.14% | 4.34% | $714 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 6.07% | 3.27% | $607 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 5.71% | 2.91% | $571 / yr |
| 🇬🇧 UK ISA | 0% | 7.14% | 4.34% | $714 / yr |
| 🇬🇧 UK Taxable | 8.75% | 6.52% | 3.72% | $652 / yr |
| 🇨🇦 TFSA | 0% | 7.14% | 4.34% | $714 / yr |
| 🇨🇦 CA Taxable | 25% | 5.35% | 2.55% | $535 / yr |
| 🇦🇺 Super (pension) | 15% | 6.07% | 3.27% | $607 / yr |
| 🇦🇺 AU Taxable | 30% | 5.00% | 2.20% | $500 / yr |
| 🇩🇪 DE Taxable | 26.375% | 5.26% | 2.46% | $526 / yr |
| 🇫🇷 FR Taxable | 30% | 5.00% | 2.20% | $500 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
AMAM pays quarterly — 4 times per year. Next ex-div: TBD.
How AMAM compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for AMAM sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2023-12-11 | 750,000 | — | — | ||
| Sale | 2023-10-27 | 50,012 | $9.82 | $491.1K | ||
| Buy | 2023-10-23 | 1,307,311 | $6.99 | $9.14M | ||
| Buy | 2023-09-18 | 751,233 | $9.24 | $6.94M | ||
| Buy | 2023-09-15 | 1,401,505 | $9.05 | $12.68M | ||
| A-Award | 2023-09-01 | 125,000 | — | — | ||
| A-Award | 2023-09-01 | 70,833 | — | — | ||
| A-Award | 2023-07-05 | 1,216,500 | $2.38 | $2.90M | ||
| A-Award | 2023-07-05 | 389,000 | $2.38 | $925.8K | ||
| A-Award | 2023-07-05 | 389,000 | $2.38 | $925.8K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the AMAM dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →